financetom
Business
financetom
/
Business
/
Ecolab Likely to Meet Q3 Expectations, Reaffirm Full-Year EPS Guidance, RBC Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ecolab Likely to Meet Q3 Expectations, Reaffirm Full-Year EPS Guidance, RBC Says
Oct 13, 2025 10:32 AM

01:00 PM EDT, 10/13/2025 (MT Newswires) -- Ecolab ( ECL ) is expected to report Q3 results in line with expectations and reaffirm its full-year earnings per share guidance as pricing tailwinds boost organic growth for the rest of the year, RBC Capital Markets said in a note Friday.

Analysts, including Ashish Sabadra, project about 4% organic revenue growth for Q3, likely driven by strength in high-tech, life sciences, institutional, and pest control businesses. Pricing could rise to around 3% in Q3 and Q4, supported by a 5% US tariff surcharge and value-based pricing strategies, analysts added.

For Q3, the analysts estimate adjusted earnings per share of $2.07, operating income of $796 million, and an operating margin of 19.3%, all in line with consensus, while revenue is likely to be slightly below consensus at $4.12 billion. For the full year, Ecolab ( ECL ) is expected to confirm its EPS guidance for $7.42 to $7.62, RBC said.

Ecolab's ( ECL ) continued focus on higher-growth areas such as data centers, microelectronics, life sciences, and digital offerings, as well as the Ovivo acquisition position the company for EPS growth of 12% to 15% in fiscal year 2026 and beyond, according to the note.

"We see Ecolab ( ECL ) as a strong franchise given over 90% recurring revenues, long-term revenue growth of 5% to 7% and normalized EPS growth of 15% based on the razor/razor blade consumable model," analysts said.

The company is scheduled to report Q3 results on Oct. 28.

RBC has an outperform rating and a $294 price target on Ecolab ( ECL ).

Price: 271.93, Change: -0.15, Percent Change: -0.06

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Marinus Pharmaceuticals Epilepsy Treatment Falls Short in Phase 3 Study
Marinus Pharmaceuticals Epilepsy Treatment Falls Short in Phase 3 Study
Jun 17, 2024
08:03 AM EDT, 06/17/2024 (MT Newswires) -- Marinus Pharmaceuticals ( MRNS ) said on Monday that its experimental drug, intravenous ganaxolone, aimed at treating refractory status epilepticus - a condition where seizures persist despite standard treatments - did not achieve one of its primary goals in a Phase 3 study, sending shares down by 8.5% in premarket trading. Marinus said...
Naver's Webtoon Entertainment targets up to $2.67 bln valuation in US IPO
Naver's Webtoon Entertainment targets up to $2.67 bln valuation in US IPO
Jun 17, 2024
June 17 (Reuters) - Online comics platform Webtoon Entertainment said on Monday it is targeting a valuation of up to $2.67 billion in its initial public offering in the United States. The company, majority-owned by South Korean tech giant Naver , is aiming to raise as much as $315 million by offering 15 million shares at a price range of...
Adventus Mining Says Key Authorization for El Domo-Curipamba Project in Ecuador Facing Legal Challenge
Adventus Mining Says Key Authorization for El Domo-Curipamba Project in Ecuador Facing Legal Challenge
Jun 17, 2024
08:06 AM EDT, 06/17/2024 (MT Newswires) -- Adventus Mining ( ADVZF ) and Salazar Resources (SRL.V) on Monday said a previously obtained key authorization for the El Domo-Curipamba project is being challenged in the Ecuadorian courts. Adventus obtained the environmental license for the mine's construction and operation phase on January 19 from the Ministry of Environment, Water, and Ecological Transition...
Top Premarket Decliners
Top Premarket Decliners
Jun 17, 2024
08:02 AM EDT, 06/17/2024 (MT Newswires) -- Ovid Therapeutics ( OVID ) shares slumped 64% Monday premarket after the company said that phase 3 studies conducted by Takeda evaluating Soticlestat in certain types of epilepsy missed their primary endpoints. Kaival Brands Innovations Group ( KAVL ) shares fell 35%, paring Friday's rally. La Rosa Holdings ( LRHC ) shares retreated...
Copyright 2023-2026 - www.financetom.com All Rights Reserved